Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT07471789
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Phase I/IIa Clinical Trial With Dose Escalation to Evaluate Safety and Efficacy of the Infusion of CART84 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Sponsor: Astrum CRO, S.L.
Conditions
Acute Myeloblastic Leukaemia Leukemia, T-Cell
Interventions
CART84
Updated 1 time since 2026 Last updated: Mar 10, 2026 Started: Feb 4, 2026 Primary completion: May 31, 2029 Completion: Feb 4, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Acute Myeloblastic Leukaemia and Leukemia, T-Cell, this trial is actively recruiting participants. The trial is conducted by Astrum CRO, S.L. and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Astrum CRO, S.L.
- Gyala Therapeutics
Data source: Gyala Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .